A share price of Zevra Therapeutics Inc [ZVRA] is currently trading at $8.27, up 9.10%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ZVRA shares have gain 9.83% over the last week, with a monthly amount glided 15.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Zevra Therapeutics Inc [NASDAQ: ZVRA] stock has seen the most recent analyst activity on September 24, 2024, when Maxim Group reiterated its Buy rating and also boosted its price target to $25 from $18. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 24, 2024, and set its price target to $17. On April 02, 2024, Maxim Group reiterated its Buy rating and revised its price target to $18 on the stock. William Blair started tracking the stock assigning a Outperform rating. Maxim Group initiated its recommendation with a Buy and recommended $12 as its price target on March 17, 2023.
Zevra Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.89 and $8.95. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Zevra Therapeutics Inc [NASDAQ: ZVRA] shares were valued at $8.27 at the most recent close of the market. An investor can expect a potential return of 153.93% based on the average ZVRA price forecast.
Analyzing the ZVRA fundamentals
Trailing Twelve Months sales for Zevra Therapeutics Inc [NASDAQ:ZVRA] were 23.99M which represents -47.47% decline. Gross Profit Margin for this corporation currently stands at 0.46% with Operating Profit Margin at -3.1%, Pretax Profit Margin comes in at -2.73%, and Net Profit Margin reading is -2.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -1.25 and Total Capital is -0.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.90 points at the first support level, and at 7.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.56, and for the 2nd resistance point, it is at 8.84.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zevra Therapeutics Inc [NASDAQ:ZVRA] is 2.00. Also, the Quick Ratio is 2.00, while the Cash Ratio stands at 1.29. Considering the valuation of this stock, the price to sales ratio is 18.14, the price to book ratio is 10.69.
Transactions by insiders
Recent insider trading involved Clifton R. LaDuane, CFO & Treasurer, that happened on Jul 17 ’24 when 2000.0 shares were purchased. Director, Anderson Thomas completed a deal on Jul 16 ’24 to buy 10000.0 shares. Meanwhile, Director Bode John B bought 10000.0 shares on Jul 12 ’24.
